CTSO — Cytosorbents Corp
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on CTSO
| date | signal | measured base rate |
|---|---|---|
| 2026-03-06 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-15 | MARIANI PETER J Chief Financial Officer | Open-market purchase | 100.0K | 0.44 | 44.0K |
| 2026-06-15 | Chan Phillip P. Chief Executive Officer | Open-market purchase | 10.3K | 0.43 | 4.4K |
| 2026-06-12 | Chan Phillip P. Chief Executive Officer | Open-market purchase | 251.1K | 0.40 | 100.5K |
| 2025-11-18 | Chan Phillip P. Chief Executive Officer | Grant or award | 100.0K | 0.64 | 64.0K |
| 2025-08-08 | Chan Phillip P. Chief Executive Officer | Grant or award | 105.6K | 0.00 | 0 |
| 2025-08-08 | Capponi Vincent President and COO | Grant or award | 89.1K | 0.00 | 0 |
| 2025-08-08 | Deliargyris Efthymios Chief Medical Officer | Grant or award | 70.0K | 0.00 | 0 |
| 2025-08-08 | MARIANI PETER J Chief Financial Officer | Grant or award | 71.5K | 0.00 | 0 |
| 2025-02-24 | Chan Phillip P. Chief Executive Officer | Out-of-the-money Exercise | 34.2K | 1.13 | 38.6K |
| 2025-02-24 | MARIANI PETER J Chief Financial Officer | Out-of-the-money Exercise | 32.6K | 1.13 | 36.9K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| AVENIR CORP | 3.0M | 5.2M |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | 1.9M |
| Skylands Capital, LLC | 967.0K | 1.7M |
| NEUBERGER BERMAN GROUP LLC | 950.8K | 1.7M |
| CM Management, LLC | 836.1K | 1.5M |
| BlackRock, Inc. | 443.4K | 783.0K |
| GEODE CAPITAL MANAGEMENT, LLC | 400.6K | 707.3K |
| Sargent Investment Group, LLC | 311.4K | 549.9K |
| Pathstone Holdings, LLC | 283.1K | 500.0K |
| VANGUARD FIDUCIARY TRUST CO | 177.6K | 313.9K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Cytosorbents Corp (CTSO) filed form 8-K · 2026-08-14 · SEC EDGAR
Ask the AI about CTSO
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →